16 results about "Toxin binding" patented technology

The invention relates to the technical field of food safety detection, in particular to a food crop pathogenic mycotoxin detection method based on double signal amplification. The core of the method is a section of linear lock-type probe containing a mycotoxin specific nucleic acid aptamer, under the condition that target mycotoxin exists in a sample, the aptamer is combined with the mycotoxin, the probe is induced to generate conformational change, and the probe is closed into annular DNA under the catalysis of DNA ligase; then, the circular DNA is used as a template, isothermal rolling circle amplification is carried out through Phi29 DNA polymerase, and a long-chain DNA product containing a large number of repetitive sequences is generated; subsequently, the long-chain product is used as a molecular scaffold, and two kinds of gold nanoparticles of which the surfaces are modified with different complementary probes are cross-linked at the same time, so that the nanoparticles are quickly gathered, the color of the solution is changed from wine red to blue or purple, and convenient visual detection is realized. The method has the outstanding advantages of ultrahigh sensitivity, rapid detection and the like, and is suitable for on-site rapid screening of mycotoxin pollution.

Products, pharmaceutical compositions, methods of use, and kits are provided for treating a patient suffering from botulinum neurotoxin intoxication. Featured are single-domain variable heavy-chain (VHH) polypeptides (antibodies) that target and neutralize the light chain (LC) protease domains of botulinum neurotoxin (BoNT), i.e., BoNT LC / A and BoNT LC / B, and that advantageously provide late and post-exposure therapy for botulism patients. The LC / A toxin-binding and LC / B toxin-binding VHH polypeptides, which can be recombinantly produced, specifically bind to the LCs of the botulinum neurotoxins to inhibit toxin activity and treat intoxication.

This invention concerns a method of using mycotoxin binder in broiler chicken feed to reduce the immunotoxicity of aflatoxin B1 and ochratoxin A. This method is implemented by mixing mycotoxin binder into broiler chicken feed contaminated with aflatoxin B1 and ochratoxin A at a certain dose, then providing the feed to broiler chickens during the rearing period. The application of this method is able to reduce the toxic impact of mixed mycotoxins on the immune system of broiler chickens by improving the immune response and protection against oxidative stress. This method provides benefits in the form of improving the health and endurance of broiler chickens and reducing economic losses in the poultry industry due to decreased performance and health of livestock.

The invention relates to an in-situ binding method for evaluating binding of Bt toxin Cry1Ac and midgut epithelial cells of cotton bollworm larvae. The method comprises the following steps: incubating and culturing midgut tissues of larvae of lepidoptera pests and a Bt toxin-containing Sf-900 II cell culture solution, carrying out immunostaining, observing and photographing through a laser confocal microscope, and finally carrying out quantitative processing on a fluorescence image by utilizing ImageJ software so as to calculate an average unit area fluorescence signal value. And further evaluating the difference between the binding amounts of the midgut epithelial cells and the Bt toxins of the larvae of different strains. The method can intuitively and accurately observe and evaluate the binding condition of the Bt toxin and the midgut epithelial cells on the premise of retaining the original structure and physiological environment of the midgut tissue of the larvae, provides direct data support for Bt resistance research, assists in analyzing the pest Bt resistance mechanism, has important significance in formulating resistance early warning and treatment strategies, and has a wide application prospect. The method is suitable for the biotechnical fields of Bt toxin insecticidal mechanism research, lepidoptera pest drug resistance mechanism exploration and the like.

Polypeptide products, methods, pharmaceutical compositions, and kits are provided for treating a subject exposed to, or at risk for exposure to, C. difficile microbial pathogens and toxin B produced by C. difficile (TcdB) pathogens. The methods, compositions and kits include a single domain, anti-TcdB VHH polypeptide (antibody), or toxin B binding portion thereof, that specifically binds to and / or neutralizes TcdB and treats or prevents illness and disease associated with C. difficile infection and TcdB intoxication. The anti-TcdB VHHs, or toxin B binding portion thereof, may be recombinantly produced.

The present invention relates to methods and compositions for detecting, diagnosing, preventing, treating or ameliorating symptoms of demyelinating disorders in human or animal subjects in need thereof, the disorders being selected from: enterotoxemia (ET), multiple sclerosis (MS), clinically confirmed MS (CDMS), clinically isolated syndrome (CIS), neuromyelitis optica spectrum disorders (NMOSD), optic neuritis (ON), neuromyelitis optica (NMO), myelitis, myelitis, transverse myelitis (TM), diseases or disorders characterized by increased or presence of antibodies to aquaporin-4 (AQP-4) and / or astrocyte damage, and acute disseminated encephalomyelitis (ADEM). The method comprises administering to the subject a composition comprising an effective amount of an agent that directly or indirectly interferes with an epsilon toxin (Etx) produced by a type B or D strain of Clostridium perfringens, an Etx-binding receptor, or the interaction of Etx with its binding receptor, thereby inhibiting or suppressing the receptor signaling activity regulated by Etx. The present invention also provides novel polypeptides useful as vaccines against diseases caused by or associated with the epsilon toxin of Clostridium perfringens.

The present disclosure provides a binding protein (e.g., an antibody) comprising at least one antigen binding domain that binds to necrotizing enteritis B-like toxin (NetB), said antigen binding domain comprising a heavy chain variable region comprising three complementarity determining regions (CDRs), preferably wherein said binding protein binds to NetB at a KD of 250 pM or less at pH 7.4. The binding proteins can be used to treat or prevent Clostridium perfringens infection or necrotic enteritis. Nucleic acid molecules, expression vectors, host cells and compositions are also provided.

The invention relates to a micro-nano system for peritoneal dialysis. The components of the micro-nano system comprise large-mass substances, such as macromolecules, polymers and tiny structures formed by specific substances. The large-mass substances have the advantage of high combining capacity with wastes / toxins in the dialysate. The micro-nano system is dissolved or suspended in the dialysate, and large-mass substances in the micro-nano system extract and enrich waste in the peritoneal dialysate during peritoneal dialysis, so that the capacity of the dialysate is enhanced.

The present disclosure provides a binding protein, e.g. an antibody, comprising at least one antigen binding domain which binds to necrotic enteritis B-like toxin (NetB), said antigen binding domain comprising a heavy chain variable region which comprises three complementarity determining regions (CDRs), preferably wherein said binding protein binds to NetB with a KD of 250 pM or less at pH 7.4. Said binding proteins can be used in the treatment or prevention of C. perfringens infection or Necrotic Enteritis. Nucleic acid molecules, expression vectors, host cells and compositions are also provided.

This invention provides a functional polymer targeting endotoxins and its applications, belonging to the fields of materials science, polymer science, and biomedical engineering. The invention designs and synthesizes a functional polymer targeting endotoxins through free radical polymerization. The functional polymer consists of an antifouling unit, an endotoxin-binding unit, and a coupling unit connecting the polymer and the endotoxin-binding unit, wherein the endotoxin-binding unit is an affinity polypeptide targeting endotoxins. In vitro and in vivo endotoxin clearance experiments show that the functional polymer exhibits high specificity and affinity for endotoxins, while also possessing good antifouling, anti-interference, and blood compatibility properties. It can achieve precise clearance of endotoxins from the blood and can be widely applied in various fields of biomedicine, such as bioseparation, biodetection, blood purification, and disease diagnosis and treatment.

The present invention is a method for detecting Verotoxin. Mass spectrometry is used to more accurately detect Verotoxin. The method for detecting Verotoxin comprises: preparing a sample and a molecule that binds to Verotoxin; performing an operation of purifying the Verotoxin in the sample by utilizing the binding of the molecule to Verotoxin; and subjecting the sample obtained by the above operation to a first mass spectrometry analysis.

The present invention relates to methods and compositions for detecting, diagnosing, preventing, treating or ameliorating symptoms of a demyelination disorder in a human or animal subject in need thereof, the present invention relates to a method for treating a disease or condition selected from the group consisting of enterotoxemia (ET), multiple sclerosis (MS), clinically definite MS (CDMS), clinically isolated syndrome (CIS), neuromyelitis optica lineage disease (NMOSD), neuromyelitis (ON), neuromyelitis optica (NMO), myelitis, myelitis, transverse myelitis (TM), a disease or condition characterized by an increase or presence of an antibody to aquaporin-4 (AQP-4) and / or astrocyte damage, and acute disseminated encephalomyelitis (ADEM). The method comprises administering to a subject a composition comprising an effective amount of an agent that directly or indirectly interferes with epsilon toxin (Etx) produced by a Clostridium perfringens type B or type D strain, Etx binding receptor, or interaction of Etx with its binding receptor, to inhibit or repress Etx modulated receptor signaling activity.

Described herein are compounds and compositions for use in treatment or prevention of an inflammatory bowel disease, gastrointestinal cancer, or a systemic bacterial infection in a subject in need thereof. The subject may be colonized by one or more pathogenic bacterial strains such as B. fragilis, E. faecalis, or C. perfringens. In certain aspects, the disclosure provides a method of diminishing the pathogenic effects of these bacterial strains by administering a compound that binds to and / or inhibits one or more toxins produced thereby.

The invention discloses a magnetic nanoprobe and a method for detecting fungaltoxin by a critical offset magnetic particle spectroscopy, the magnetic nanoprobe is formed by modifying the surface of a Fe3O4 magnetic nanoparticle with an antibody capable of specifically recognizing fungaltoxin, the antibody is coupled with an aldehyde group through an amino group modified on the surface of the Fe3O4 nanoparticle, and the magnetic nanoprobe is formed by detecting the fungaltoxin. Stable covalent linkage is formed, and targeted recognition and combination of the aflatoxin B1 and the deoxynivalenol are achieved. The magnetic nanoprobe adopted by the invention can realize detection and quantification of the target toxin through a critical offset magnetic particle spectrum technology under an unmarked condition, the nonlinear response of the Fe3O4 nanoparticles is excited through a bias magnetic field, and by measuring the magnetic phase change generated before and after the Fe3O4 nanoparticles are combined with the toxin, the detection and quantification of the target toxin can be realized. The sensitive detection on the target toxin is realized. The method has the advantages of high detection sensitivity, no elution operation, rapidness, low cost and the like.

A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC / peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.

An intra-oral, nanoemulsion blend is provided that enhances liver and toxin excretion performance in mammals when orally administered. A solid powder toxin binding composition also is provided that may be used to irreversibly bind the toxins reaching the bowel so that once the toxins are excreted into the bowel, they may not be reabsorbed, and are thus eliminated. A method of administering the nanoemulsion blend and the toxin binding composition to enhance toxin excretion also is described. The nanoemulsion blend is ingestible and edible.